Clinical Trial: Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Comparative Trial of the Efficacy of Two Different Nolvadex (NDX) Dosing and Scheduling Regimens in Preventing Gynecomastia Induced by Casodex (CDX) 150 Monotherapy in P

Brief Summary: The aim of the study is to investigate the efficacy of different dosing and scheduling of Nolvadex in preventing gynecomastia/mastalgia induced by Casodex 150 mg monotherapy in patients with prostate cancer.

Detailed Summary:
Sponsor: AstraZeneca

Current Primary Outcome: Incidence of Gynecomastia and Breast pain at 2, 6 months and every 6 months thereafter and/or at withdrawal visit.

Original Primary Outcome: Same as current

Current Secondary Outcome: Sexual functioning, Quality of life.

Original Secondary Outcome: Same as current

Information By: AstraZeneca

Dates:
Date Received: October 4, 2005
Date Started: December 2003
Date Completion:
Last Updated: January 25, 2011
Last Verified: January 2011